BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu DY, Liu JC, Liang S, Meng XH, Greenbaum J, Xiao HM, Tan LJ, Deng HW. Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics. Pharmaceutics 2021;13:545. [PMID: 33919660 DOI: 10.3390/pharmaceutics13040545] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 MotieGhader H, Safavi E, Rezapour A, Amoodizaj FF, Iranifam RA. Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis. Sci Rep 2021;11:21872. [PMID: 34750486 DOI: 10.1038/s41598-021-01410-3] [Reference Citation Analysis]
2 Alhadrami HA, Alkhatabi H, Abduljabbar FH, Abdelmohsen UR, Sayed AM. Anticancer Potential of Green Synthesized Silver Nanoparticles of the Soft Coral Cladiella pachyclados Supported by Network Pharmacology and In Silico Analyses. Pharmaceutics 2021;13:1846. [PMID: 34834261 DOI: 10.3390/pharmaceutics13111846] [Reference Citation Analysis]
3 Aquino A, Paschoalin VMF, Tessaro LLG, Raymundo-pereira PA, Conte-junior CA. Updating the use of nano-biosensors as promising devices for the diagnosis of coronavirus family members: A systematic review. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lu Y, Tseng L, Huang Y, Yang C, Chen Y, Chen H. The Potential Complementary Role of Using Chinese Herbal Medicine with Western Medicine in Treating COVID-19 Patients: Pharmacology Network Analysis. Pharmaceuticals 2022;15:794. [DOI: 10.3390/ph15070794] [Reference Citation Analysis]
5 Oh K, Adnan M, Cho D. Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19. CIMB 2022;44:1597-609. [DOI: 10.3390/cimb44040109] [Reference Citation Analysis]
6 Xiang Y, Wong KC, So HC. Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities. Pharmaceutics 2021;13:1514. [PMID: 34575590 DOI: 10.3390/pharmaceutics13091514] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:691. [PMID: 34358117 DOI: 10.3390/ph14070691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]